R U Txtng Px Yet?
Pfizer Picks Exco SMS
Exco InTouch discusses Pfizer’s endorsement, and the use of its technology in a new type of project.
Hedge funds have been making waves in the clinical development industry for years, snapping up contract research organizations (CRO) with publicly-listed shares and putting them in private hands. Now the game appears to be shifting to undervalued technology firms. Genstar finalized the $400 million purchase of ERT, the #1 cardiac core lab, earlier this month. This week, Genstar wrote a second check. For an undisclosed sum, the private equity group added a top electronic patient diary provider, Pittsburgh’s invivodata, to the ERT portfolio. Based in San Francisco, Genstar is no stranger to clinical research. It purchased PRA International for $790 million in 2007. Genstar isn’t telegraphing whether it is considering a potential combination of PRA and ERT. That move would mirror some of the assets at Parexel, which Wall Street does appear to understand. It may not be clear for years whether such a move would please customers in pharma (by…more...
At its annual customer conference last week in its home town of Boston, PHT reviewed the last few years of growth in the electronic patient-reported outcome (ePRO) niche. Business has been…more...
With the basic features and functions in place, many providers of clinical trial software are busy refining the ways that users get information in and out. Reports have been newly modernized…more...
Major electronic diary providers all built their platforms around a Windows or Palm-based device that plugs into an electrical outlet. But that dependence on hardware is a bit cloudy going forward,…more...
Safety. Efficacy. Are those two cardinal notions of clinical development enough? Jean Paty has a third. He believes it is as central as safety and efficacy. Paty is co-founder and senior VP of scientific, quality and regulatory affairs at invivodata, a Pittsburgh, Penn., electronic patient diary firm. If safety and efficacy are the X and Y axes…more...
After doing 20 trials together, Quintiles and ediary supplier invivodata announced a closer partnership. For the large contract research organization, the relationship likely brings additional scientific firepower to a research niche newly legitimized by a final FDA guidance document in patient reported outcomes (PRO). For the Pittsburgh ediary supplier, meanwhile, the relationship will bring more projects and…more...
Hey! Can you reset my password? Now? Inside or outside the clinical trial world, that is one of the most mundane and routine requests made to software help desks. Ediary firm PHT says the ongoing hassle has now been simplified in its StudyWorks system. The system has now been updated to allow users to administer their own…more...
CRF has noticed a funny thing about patients filling out clinical trial diaries in India and eastern Europe. The data are immaculate. The patients are highly compliant, to the tune of doing 95-98 percent of what they’re supposed to. Rachael King, the new CEO at CRF, isn’t sure what cultural factors explain that performance. “It’s very hard…more...
Exco InTouch discusses Pfizer’s endorsement, and the use of its technology in a new type of project.
How Arrowhead Electronic Healthcare double-checked 2,698 forms for a global trial using ediaries in 19 languages.
The Pittsburgh diary company invivodata has been dredging up facts about patient-reported outcomes.
With a sleek computer for sites, the Pittsburgh firm offers a larger canvas for electronic patient-reported outcomes (ePRO).
Two top firms, each specializing in different approaches to gathering patient experiences, will partner to help sponsors find the right technology.
At a user meeting later this month, invivodata will unveil a new device from a company other than Palm.
Using a tablet PC and the Apple phone, assiTek says larger screens can be helpful to science and sites.
Organizations
Conferences
Info & Opinion
© 2013 ClinPage. All Rights Reserved.